18 ALLY Robotic Cataract Laser Systems® (“ALLY Systems”) placed in 3Q 2025; Backlog of 18 ALLY Systems pending installation as of September 30, 2025 ALLY installed base grew 77% and total laser installed base grew 20% over 3Q 2024 ORLANDO, Fla., Nov. 06, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the quarter ended Septemb ...

18 ALLY Robotic Cataract Laser Systems™ ("ALLY Systems") placed in 2Q 2025 with an additional backlog of 18 ALLY Systems pending installation as of June 30, 2025 ALLY installed base grew 107% and total installed base grew 23% over 2Q 2024 Worldwide procedure volumes increased 23% over 2Q 2024 ORLANDO, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or the "Company), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, t ...

Core Insights - LENSAR, Inc. reported a strong start to 2025 with a 34% increase in revenue and a 33% rise in worldwide procedure volumes compared to the first quarter of 2024 [2][3] - The company placed 14 ALLY Robotic Laser Cataract Systems in the first quarter of 2025, contributing to a total installed base of approximately 150 systems [3][4] - The company is in the process of a proposed merger with Alcon Research, LLC, which has led to increased acquisition-related costs [4][8] Financial Performance - Total revenue for Q1 2025 was $14.2 million, up from $10.6 million in Q1 2024, marking a $3.6 million increase [3][4] - Recurring revenue for the quarter was $11.5 million, representing an 81% recurring revenue percentage, although this is down from 90% in the previous year [4] - The net loss for Q1 2025 was $27.3 million, compared to a net loss of $2.2 million in Q1 2024, primarily due to changes in warrant liability [6][7] Operational Highlights - The company’s laser systems accounted for approximately 22% of total U.S. procedures in Q1 2025 [3] - Selling, general, and administrative expenses increased by 64% to $11.1 million, largely due to acquisition-related costs associated with the Alcon merger [4] - Research and development expenses rose slightly to $1.5 million, a 6% increase from the previous year [5] Cash Position - As of March 31, 2025, LENSAR had cash, cash equivalents, and investments totaling $25.2 million, an increase from $22.5 million at the end of 2024 [8]

31 ALLY Robotic Cataract Laser Systems™ placed in Q4 2024, representing an 86% increase in ALLY placements in full year 2024 over 2023; Company’s total installed systems increased to approximately 385 as of December 31, 2024, representing a 26% increase over 2023 Fourth quarter 2024 revenue increased 38% over fourth quarter 2023; Full-year revenue increased 27% over 2023 Recurring revenue exceeds $40 million for the full year; increased 23% over 2023 ORLANDO, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE) -- LENSAR, ...